For patients with amyloidosis, the difference between receiving the right treatment and the wrong one can hinge on a deceptively simple question: which protein is actually forming the deposits? Amyloidosis is not one disease but a family of disorders in which misfolded proteins accumulate in organs as insoluble fibrils, gradually destroying the heart, kidneys, nerves, or other tissues. Each type demands a different therapeutic strategy, from chemotherapy for light chain disease to liver transplantation or gene-silencing drugs for transthyretin amyloidosis. Now, researchers at Stanford University have unveiled a streamlined mass spectrometry workflow that could bring the most accurate form of amyloid typing within reach of many more clinical laboratories, cutting sample preparation to under eight hours while abandoning the expensive nanoflow equipment that has long limited access to the technology.
Mass spectrometry-based amyloid typing has earned a reputation as the gold standard for identifying the amyloidogenic protein in tissue deposits. By shredding laser-microdissected amyloid plaques into peptides and reading their mass spectra, laboratories can distinguish among more than thirty amyloid types with a specificity that immunohistochemistry and immunofluorescence simply cannot match. Yet the technique has remained confined largely to a handful of reference laboratories because it depends on nanoflow liquid chromatography, in which solvents are pushed through capillaries with inner diameters measured in tens of micrometers. Nanoflow systems deliver exquisite sensitivity, but they come with steep up-front costs, demanding maintenance, long column equilibration times, and a level of operational complexity that deters routine clinical adoption.
The Stanford team, led by Morgan W. Mann and Fangjun Chen with senior authors Megan L. Troxell and Ruben Y. Luo, set out to re-engineer the workflow so that it could run on the high-flow liquid chromatography systems already humming away in hospital laboratories. Their solution rests on two complementary innovations: a sample preparation method called suspension trapping, known commercially as S-Trap, and an acquisition strategy known as data-independent acquisition, or DIA. Together, these techniques allow the analysis of microdissected amyloid plaques using conventional-flow chromatography coupled to tandem mass spectrometry, without sacrificing the diagnostic accuracy that clinicians rely upon.
Suspension trapping is the quieter revolution of the two. In traditional proteomics sample preparation, proteins extracted from tiny tissue fragments must be digested into peptides through a series of solution exchanges, buffer removals, and cleanups that consume time and lose precious material at every step. The S-Trap approach instead traps proteins on a quartz filter matrix as they precipitate out of an acidic methanol-containing buffer. Digestion enzymes then pass through the trap, generating peptides that are eluted in a single, efficient step. The method is fast, robust, and minimizes sample loss, which matters enormously when the starting material consists of a few thousand cells harvested by laser capture microdissection from a formalin-fixed paraffin-embedded tissue section.
Data-independent acquisition addresses the other half of the problem. In classical data-dependent acquisition, the mass spectrometer selects the most intense ions in each scan for fragmentation, a stochastic process that can miss low-abundance peptides and produces data that are tedious to align across runs. DIA, by contrast, fragments all ions within successive wide mass windows, systematically recording fragment spectra for essentially everything in the sample. The resulting data are reconstructed computationally against spectral libraries, yielding consistent and quantitative peptide identifications. Because DIA tolerates the higher flow rates, wider chromatographic peaks, and greater sample loads of high-flow chromatography, it made the leap away from nanoflow feasible rather than merely aspirational.
To translate raw proteomic data into a diagnosis, the researchers also developed a custom selection heuristic that sifts through the hundreds of proteins detected in each plaque and identifies the most likely amyloidogenic culprit. Amyloid deposits are not pure; they sweep up serum proteins, immunoglobulin fragments, and extracellular matrix components as they form. Distinguishing the genuine amyloidogenic protein from innocent bystanders requires weighing total protein abundance, the presence of type-specific signature peptides, and the biological plausibility of each candidate. The heuristic automates this judgment, reducing an expert curation task that could take hours into a reproducible computational step suitable for a busy clinical workflow.
The performance data are striking. Working with laser capture microdissected plaques from 47 patient samples, 10 from cardiac biopsies and 37 from renal biopsies, the team split the material into a training set of 25 samples and an independent testing set of 22. The high-flow LC-DIA-MS/MS method identified the amyloidogenic protein in approximately 96 percent of plaques in both sets, a success rate comparable to established nanoflow approaches. The two inaccuracies observed across the cohort both traced to difficulties in identifying immunoglobulin lambda proteins, once in a specimen obtained after treatment had altered the composition of the deposits and once in a plaque containing two distinct amyloid types simultaneously. These edge cases, the authors note, define the boundaries of the method rather than undermining its general utility.
Reducing the sample preparation workflow to under eight hours carries practical significance beyond convenience. Amyloidosis is increasingly recognized as an urgent diagnosis; cardiac involvement can progress rapidly, and new therapies such as transthyretin stabilizers and silencing agents work best when started early. Every hour shaved from the analytical pipeline shortens the time between biopsy and answer. Equally important, the shift to high-flow chromatography means the method can run on instruments of the kind already deployed for clinical chemistry assays, drug monitoring, and newborn screening in hospital laboratories. That compatibility could transform amyloid typing from a rarefied referral test into an accessible diagnostic performed locally, at lower cost and with faster turnaround.
The study, published in Clinical Proteomics, was conducted on remnant patient specimens under approved institutional review board protocols and funded through the Stanford University Department of Pathology’s Test Development Program, underscoring its explicitly clinical orientation. The authors acknowledge one commercial entanglement: a collaborative research relationship between one investigator and Thermo Fisher Scientific, which provided technical support. While the method will still require validation in other laboratories and across broader panels of amyloid types, the combination of suspension trapping, data-independent acquisition, and high-flow chromatography represents a credible path toward democratizing molecular amyloid typing, offering patients everywhere the prospect of a faster, more precise answer to the question their treatment ultimately depends on.
Subject of Research: A high-flow liquid chromatography-tandem mass spectrometry method for typing amyloidosis in clinical laboratories
Article Title: Suspension trapping and data-independent acquisition enable high-flow liquid chromatography-tandem mass spectrometry-based amyloidosis typing in clinical laboratories
Article References: Mann, M. W., Chen, F., Zhu, C., Lu, C., Liang, B., Kambham, N., Troxell, M. L., & Luo, R. Y. (2026). Suspension trapping and data-independent acquisition enable high-flow liquid chromatography-tandem mass spectrometry-based amyloidosis typing in clinical laboratories. Clinical Proteomics. https://doi.org/10.1186/s12014-026-09628-x
Image Credits: AI Generated
DOI: 10.1186/s12014-026-09628-x
Keywords: amyloidosis, mass spectrometry, proteomics, data-independent acquisition, suspension trapping, liquid chromatography, clinical diagnostics, laser capture microdissection, AL amyloidosis, ATTR amyloidosis, tandem mass spectrometry, clinical proteomics
Cite Scienmag News
APA
MLA
Chicago
Ophelia Keating. (September 12, 2026). Faster Amyloidosis Typing with High-Flow Mass Spectrometry Reaches the Clinic. Scienmag. https://scienmag.com/faster-amyloidosis-typing-with-high-flow-mass-spectrometry-reaches-the-clinic/
Ophelia Keating. “Faster Amyloidosis Typing with High-Flow Mass Spectrometry Reaches the Clinic.” Scienmag, 12 September 2026, https://scienmag.com/faster-amyloidosis-typing-with-high-flow-mass-spectrometry-reaches-the-clinic/. Accessed 12 September 2026.
Ophelia Keating. “Faster Amyloidosis Typing with High-Flow Mass Spectrometry Reaches the Clinic.” Scienmag. September 12, 2026. https://scienmag.com/faster-amyloidosis-typing-with-high-flow-mass-spectrometry-reaches-the-clinic/
Copy citation
Download RIS
Tags: AL amyloidosisamyloid disease subtypingamyloid protein identificationamyloidosisamyloidosis diagnosisATTR amyloidosisclinical amyloidosis testingclinical diagnosticsclinical proteomicsdata-independent acquisitionhigh-throughput mass spectrometryinnovative diagnostic workflowslaser capture microdissectionliquid chromatographymass spectrometrymass spectrometry amyloid typingnanoflow mass spectrometry limitationsorgan-specific amyloidosisProteomicsrapid amyloid sample processingStanford amyloidosis researchsuspension trappingtandem mass spectrometrytargeted amyloid therapy differentiation
